,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1189,1,5,,48414597,4510,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
1,1205,1,4,,48414597,4510,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
2,1208,1,3,,48414597,4510,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
3,58416,3,4,,103198242,4510,Unspecified,,,,,Percent change in left ventricle contractile force in anesthetized dogs after intravenous administration at 0.3 mg/kg,Other,1654425.0,
4,58418,3,4,,103198242,4510,Unspecified,,,,,Percent change in left ventricle contractile force in anesthetized dogs after intravenous administration at 1.0 mg/kg,Other,1654425.0,
5,58420,3,4,,103198242,4510,Unspecified,,,,,Percent change in left ventricle contractile force in anesthetized dogs after intravenous administration at 3.0 mg/kg,Other,1654425.0,
6,59574,3,3,,103198242,4510,Unspecified,,,,,"Maximum hypertension was measured in anesthetized dog as percent at the dose of 0.03 mg/kg, i.v.",Other,12699747.0,
7,59741,3,4,,103198242,4510,Unspecified,,,,,"Maximum collateral index in anesthetized dog at the dose of 0.03 mg/kg, i.v.",Other,12699747.0,
8,60299,3,3,,103198242,4510,Unspecified,,,,,"Collateral index in anesthetized dog at the dose of 0.03 mg/kg, i.v. after 60 minutes of administration",Other,12699747.0,
9,60813,3,4,,103198242,4510,Unspecified,,,,,Percent change in mean arterial blood pressure after intravenous administration in anesthetized dogs at 0.3 mg/kg,Other,1654425.0,
10,60814,3,4,,103198242,4510,Unspecified,,,,,Percent change in mean arterial blood pressure after intravenous administration in anesthetized dogs at 1.0 mg/kg,Other,1654425.0,
11,60816,3,4,,103198242,4510,Unspecified,,,,,Percent change in mean arterial blood pressure after intravenous administration in anesthetized dogs at 3.0 mg/kg,Other,1654425.0,
12,60819,6,1,,103198242,4510,Unspecified,,,,,Percent change heart rate after intravenous administration in anesthetized dogs at 0.3 mg/kg (NC<10%),Other,1654425.0,
13,60820,6,1,,103198242,4510,Unspecified,,,,,Percent change heart rate after intravenous administration in anesthetized dogs at 1.0 mg/kg,Other,1654425.0,
14,60821,6,1,,103198242,4510,Unspecified,,,,,Percent change in heart rate after intravenous administration in anesthetized dogs at 3.0 mg/kg (NC<10%),Other,1654425.0,
15,76451,3,3,,103198242,4510,Unspecified,,,,,In vitro NO (nitrous oxide) release by nitrite quanititation using Griess reaction without N-acetyl-cysteamine,Other,11831908.0,
16,76452,3,3,,103198242,4510,Unspecified,,,,,In vitro NO (nitrous oxide) release by nitrite quanititation using Griess reaction in presence of N-acetyl-cysteamine,Other,11831908.0,
17,77510,3,3,,103198242,4510,Unspecified,,,,,In vitro release of nitric oxide by nitrite quantitation in the absence of N-acetyl-cysteamine by Griess reaction,Other,10498219.0,
18,77511,3,3,,103198242,4510,Unspecified,,,,,In vitro release of nitric oxide by nitrite quantitation in the presence of N-acetyl-cysteamine by Griess reaction,Other,10498219.0,
19,77513,3,4,,103198242,4510,Unspecified,,,,,In vitro nitric oxide release incubated in the absence of N-acetyl-cysteamine in phosphate buffer,Other,14695839.0,
20,77514,3,4,,103198242,4510,Unspecified,,,,,In vitro nitric oxide release incubated in the presence of N-acetyl-cysteamine in phosphate buffer,Other,14695839.0,
21,167355,6,3,,103198242,4510,Active,,,0.016,IC50,Vasorelaxation activity in the isolated endothelium-denuded rabbit aorta,Confirmatory,7837224.0,
22,167787,3,3,,103198242,4510,Unspecified,,,,,Myocardial infarction (MI) size was calculated as a percentage of the infarct area to the total area of the left ventricle of male chinchilla rabbits,Other,9871565.0,
23,173808,3,4,,103198242,4510,Unspecified,,,,,Concentration required to reduce mean arterial blood pressure in rat after intravenous administration.,Other,7837224.0,
24,175471,6,3,,103198242,4510,Active,,,0.022000000000000002,EC50,Capacity to increase [Ca2+] entry into the vascular smooth muscle was evaluated on rat aorta strips partially depolarized with 50 mM K,Confirmatory,15115410.0,
25,175492,6,3,,103198242,4510,Active,,,2.2,EC50,Compound was tested for its vasodilator effects on endothelium-denuded strips of rat aorta precontracted with noradrenaline,Confirmatory,7996554.0,
26,175666,6,3,,103198242,4510,Active,,,1.9,EC50,"Effective concentration for relaxation of isolated rat aortic strips, submaximally contracted with phenylephrine at 0.1 uM was determined",Confirmatory,12270164.0,
27,178068,6,2,,103198242,4510,Unspecified,,,,,Inhibition of methacholine-induced ECG changes in the anesthetized rat after intravenous administration.,Other,7837224.0,
28,178994,6,2,,103198242,4510,Unspecified,,,,,Inhibition of vasopressin-induced ECG changes in rat,Other,7837224.0,
29,187573,3,4,,103198242,4510,Unspecified,,,,,Percent recovery of noradrenergic tone after washing aortic preparations with fresh Kreb's buffer,Other,7996554.0,
30,195179,6,3,,103198242,4510,Active,,,0.0224,EC50,Relaxation of endothelium denucleated strips of rat aorta precontracted with noradrenaline,Confirmatory,9046336.0,
31,218879,6,2,,103198242,4510,Active,,,0.01,EC50,In vitro vascular relaxation in canine coronary arteries precontracted with prostaglandin F2alpha.,Confirmatory,1654425.0,
32,218881,6,2,,103198242,4510,Active,,,0.006999999999999999,EC50,In vitro vascular relaxation in canine mesenteric veins precontracted with phenylephrine.,Confirmatory,1654425.0,
33,219085,5,3,,103198242,4510,Inactive,,,,,In vitro increase in contractile force in ferret papillary muscle strips (NR = not reached at 100 ug),Other,1654425.0,
34,225247,8,2,,103198242,4510,Inactive,,,,,Inhibition of crude cAMP phosphodiesterase from canine cardiac aorta (NR = no effect at 100 ug),Other,1654425.0,
35,225250,8,3,,103198242,4510,Inactive,,,,,Inhibition of crude cGMP phosphodiesterase from canine thoracic aorta (NR = no effect at 100 ug),Other,1654425.0,
36,226296,3,3,,103198242,4510,Unspecified,,,,,Ratio of the CIAUC value to that of nitroglycerin (NTG ratio),Other,12699747.0,
37,227028,6,1,,103198242,4510,Unspecified,,,,,Nitric oxide released from prodrug in the absence of cysteine,Other,9046336.0,
38,227030,6,1,,103198242,4510,Unspecified,,,,,Nitric oxide released from prodrug in the presence of cysteine,Other,9046336.0,
39,232773,3,3,,103198242,4510,Unspecified,,,,,Selectivity index as the ratio of doses requires to induce a reduction in MABP and that required to prevent ECG changes.,Other,7837224.0,
40,245849,3,6,,103198242,4510,Unspecified,,,,,Concentration required for relaxation of PGF2-alpha (3 uM)-precontracted porcine pulmonary arteries; activity expressed as pD2,Other,15341967.0,
41,309710,6,2,,103198242,4510,Active,,,0.0356,EC50,Vasodilatory effect in pig pulmonary artery assessed as inhibition of PGF2-alpha-induced contraction,Confirmatory,17855086.0,
42,311367,3,6,,103198242,4510,Unspecified,,,,,Permeability coefficient in human skin,Other,17827020.0,
43,318681,7,1,,103198242,4510,Unspecified,,,,,Anticarcinogenic activity in rat assessed as induction of tumors per day,Other,18295489.0,
44,321898,3,3,,103198242,4510,Unspecified,,,,,Nitric oxide release in PBS at pH 7.4 in 37 degC after 1.5 hrs,Other,18096394.0,
45,321900,3,3,,103198242,4510,Unspecified,,,,,Nitric oxide release in PBS in presence of 5 mM L-cysteine at pH 7.4 in 37 degC after 1.5 hrs,Other,18096394.0,
46,352262,5,2,,103198242,4510,Active,,,0.027000000000000003,EC50,Vasorelaxant activity in pig pulmonary artery by organ bath experiment,Confirmatory,19406636.0,
47,352494,3,3,,103198242,4510,Unspecified,,,,,Nitric oxide release in phosphate buffer containing 5 mM L-cysteine at pH 7.4 incubated at 34 degC after 1.5 hrs,Other,19419861.0,
48,352500,3,3,,103198242,4510,Unspecified,,,,,Nitric oxide release in phosphate buffer at pH 7.4 incubated at 34 degC after 1.5 hrs,Other,19419861.0,
49,374756,6,2,,103198242,4510,Active,,,4.4,EC50,Vasodilatory activity in Wistar rat endothelium-denuded cross tolerant thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction preincubated with 0.55 mM GTN for 1 hr followed by washing,Confirmatory,19438239.0,
50,374757,6,2,,103198242,4510,Active,,,0.028999999999999998,EC50,Vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction,Confirmatory,19438239.0,
51,374758,6,2,,103198242,4510,Active,,,0.42,EC50,Vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction drug treated 30 mins after ALDH2 inhibitor benomyl treatment,Confirmatory,19438239.0,
52,374759,6,2,,103198242,4510,Active,,,0.94,EC50,Vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction drug treated 30 mins after ALDH2 inhibitor chloral hydrate treatment,Confirmatory,19438239.0,
53,374760,6,2,,103198242,4510,Unspecified,,,100.0,EC50,Vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction drug treated 30 mins after 1 uM soluble guanylate cyclase heme site inhibitor ODQ treatment,Confirmatory,19438239.0,
54,374762,3,4,,103198242,4510,Unspecified,,,,,Ratio of EC50 for vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring in presence of benomyl to EC50 for vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring,Other,19438239.0,
55,374763,3,4,,103198242,4510,Unspecified,,,,,Ratio of EC50 for vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring in presence of chloral hydrate to EC50 for vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring,Other,19438239.0,
56,374764,3,4,,103198242,4510,Unspecified,,,,,Ratio of EC50 for vasodilatory activity in Wistar rat endothelium-denuded cross tolerant thoracic aortic ring preincubated with 0.55 mM GTN for 1 hr followed by washing to EC50 for vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring,Other,19438239.0,
57,395247,3,3,,103198242,4510,Unspecified,,,,,Cardiac protection in Wistar rat assessed as decrease in infarct size at 5 ug/min/kg for 13 hrs prolonged treatment terminated 3 hrs before ischemia,Other,18787169.0,
58,409957,3,9,,103198242,4510,Inactive,124028637.0,281293.0,,,Inhibition of bovine liver MAOA,Other,18834112.0,
59,437026,3,4,,103198242,4510,Active,,,,,Induction of NO release in Wistar rat liver homogenate at 200 uM by amperometric detection method,Other,19595600.0,
60,437027,6,2,,103198242,4510,Active,,,0.058879999999999995,IC50,Vasorelaxant activity in endothelium-denuded Wistar rat thoracic aortic ring assessed as inhibition of KCl-induced contraction,Confirmatory,19595600.0,
61,437029,3,3,,103198242,4510,Unspecified,,,,,Inhibition of ADP-induced platelet aggregation in human platelet-rich plasma at 100 uM treated 2 mins before ADP challenge by turbidimetric method,Other,19595600.0,
62,457931,3,3,,103198242,4510,Unspecified,,,,,Induction of NO release in phosphate buffer at pH 7.4,Other,20097072.0,
63,457932,3,3,,103198242,4510,Unspecified,,,,,Induction of NO release in presence of 5 mM L-cysteine,Other,20097072.0,
64,496817,4,2,,103198242,4510,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma cruzi,Confirmatory,20185316.0,
65,496818,4,2,,103198242,4510,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei brucei,Confirmatory,20185316.0,
66,496819,4,2,,103198242,4510,Inconclusive,,,,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
67,496820,4,2,,103198242,4510,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20185316.0,
68,496821,4,2,,103198242,4510,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania,Confirmatory,20185316.0,
69,496823,4,2,,103198242,4510,Inconclusive,,,,IC50,Antimicrobial activity against Trichomonas vaginalis,Confirmatory,20185316.0,
70,496824,4,2,,103198242,4510,Inconclusive,,,,IC50,Antimicrobial activity against Toxoplasma gondii,Confirmatory,20185316.0,
71,496825,4,2,,103198242,4510,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania mexicana,Confirmatory,20185316.0,
72,496826,4,2,,103198242,4510,Inconclusive,,,,IC50,Antimicrobial activity against Entamoeba histolytica,Confirmatory,20185316.0,
73,496827,4,2,,103198242,4510,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania amazonensis,Confirmatory,20185316.0,
74,496828,4,2,,103198242,4510,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania donovani,Confirmatory,20185316.0,
75,496829,4,2,,103198242,4510,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania infantum,Confirmatory,20185316.0,
76,496830,4,2,,103198242,4510,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania major,Confirmatory,20185316.0,
77,496831,4,2,,103198242,4510,Inconclusive,,,,IC50,Antimicrobial activity against Cryptosporidium parvum,Confirmatory,20185316.0,
78,496832,4,2,,103198242,4510,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei rhodesiense,Confirmatory,20185316.0,
79,497005,4,2,,103198242,4510,Inconclusive,,,,IC50,Antimicrobial activity against Pneumocystis carinii,Confirmatory,20185316.0,
80,588211,2,3,,103198242,4510,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
81,588212,2,3,,103198242,4510,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
82,588213,2,3,,103198242,4510,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
83,624349,1,2,,92308219,4510,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
84,625279,1,3,,103198242,4510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
85,625280,1,3,,103198242,4510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
86,625281,1,3,,103198242,4510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
87,625282,1,3,,103198242,4510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
88,625283,1,3,,103198242,4510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
89,625284,1,3,,103198242,4510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
90,625285,1,3,,103198242,4510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
91,625286,1,3,,103198242,4510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
92,625287,1,3,,103198242,4510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
93,625288,1,3,,103198242,4510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
94,625289,1,3,,103198242,4510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
95,625290,1,3,,103198242,4510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
96,625291,1,3,,103198242,4510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
97,625292,1,3,,103198242,4510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
98,641620,3,2,,103198242,4510,Active,,,0.12589,IC50,Vasorelaxation activity against KCl-induced contraction in isolated Wistar rat thoracic endothelium-denulated aortic rings,Confirmatory,21992176.0,
99,720641,1,2,,92308219,4510,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
100,720717,1,3,,92308219,4510,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
101,733826,2,1,,103198242,4510,Active,,,0.12589,IC50,Vasorelaxant activity in Wistar rat endothelium-removed thoracic aortic rings assessed as reduction of KCl-induced vasoconstriction treated after KCl-challenge,Confirmatory,23534442.0,
102,733827,1,2,,103198242,4510,Unspecified,,,,,Vasorelaxant activity in Wistar rat endothelium-removed thoracic aortic rings assessed as reduction of KCl-induced vasoconstriction at 0.001 uM to 10 uM treated after KCl-challenge relative to control,Other,23534442.0,
103,1067178,1,1,,103198242,4510,Unspecified,,,180.0,IC50,Inhibition of alpha-glucosidase (unknown origin) assessed as hydrolysis of pNP-alpha-Glu into pNP measured for 10 mins by spectrophotometric analysis,Confirmatory,24508143.0,
104,1067179,1,1,,103198242,4510,Unspecified,,,,,Induction of nitric oxide release at 10'-4 M after 1 hr by Griess assay in presence of L-cysteine relative to control,Other,24508143.0,
105,1122381,1,1,,103198242,4510,Unspecified,,,,,Activation of soluble guanylate cyclase (unknown origin) assessed as apparent initial rate of oxidation of oxyhemoglobin in presence of cysteine,Other,,
106,1122383,1,1,,103198242,4510,Active,,,,,Activation of soluble guanylate cyclase (unknown origin) assessed as apparent initial rate of oxidation of oxyhemoglobin,Other,,
107,1122385,3,1,,103198242,4510,Inactive,,,,EC50,Activation of Sprague-Dawley rat soluble guanylate cyclase after 10 mins,Confirmatory,,
108,1122387,3,1,,103198242,4510,Unspecified,,,200.0,EC50,Activation of Sprague-Dawley rat soluble guanylate cyclase after 10 mins in presence of cysteine,Confirmatory,,
109,1159620,1,1,,103198242,4510,Active,,,,,Summary of drug indications.,Other,,
110,1259407,1,1,,363902039,4510,Inactive,,,,,CCRIS mutagenicity studies,Other,,
111,1259423,1,2,,354933221,4510,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
